Brett Gurkin, MD
Psychiatry · Wilmington, NCNPI 1053355719
Payments from drug & device makers
Across 735 payments — averaging $13.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$893
- Neurocrine Biosciences, Inc.$647
- plus $3K from 12 others
What the payments were for
- Food & beverage$9,63598%
- Education$2452%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 157 | $2,095 |
| Teva Pharmaceuticals USA, Inc. | 140 | $1,471 |
| Alkermes, Inc. | 56 | $1,032 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 74 | $1,012 |
| Otsuka America Pharmaceutical, Inc. | 71 | $893 |
| Neurocrine Biosciences, Inc. | 51 | $647 |
| Vanda Pharmaceuticals Inc. | 30 | $507 |
| E.r. Squibb & Sons, L.L.C. | 26 | $503 |
| AbbVie(2 entities) | 39 | $413 |
| Indivior Inc. | 26 | $358 |
| Sunovion Pharmaceuticals Inc. | 40 | $286 |
| Lundbeck LLC | 13 | $208 |
| Axsome Therapeutics, Inc. | 3 | $168 |
| Novo Nordisk | 1 | $123 |
| Noven Therapeutics, LLC | 5 | $95 |
| Janssen Scientific Affairs, LLC | 1 | $43 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,880 in reported general payments places this provider in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 568 | $1,852,355 |
| IngrezzaValbenazine Tosylate | 38 | $306,263 |
| Abilify MaintenaAripiprazole | 96 | $277,048 |
| CaplytaLumateperone Tosylate | 70 | $114,582 |
| AustedoDeutetrabenazine | 13 | $62,360 |
| RexultiBrexpiprazole | 31 | $56,486 |
| UzedyRisperidone | 24 | $52,936 |
| SublocadeBuprenorphine | 19 | $40,420 |
| Clozapine | 355 | $34,416 |
| LybalviOlanzapine/Samidorphan Malate | 11 | $18,250 |
| Paliperidone ErPaliperidone | 117 | $16,851 |
| Chlorpromazine Hcl | 38 | $14,654 |
| VraylarCariprazine Hcl | 11 | $13,620 |
| ZyprexaOlanzapine | 11 | $11,624 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 72 | $11,257 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $2,095 | $1,852,355568 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $893 | $333,534127 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $647 | $306,26338 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy | $1,471 | $115,29637 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,012 | $114,58270 claims |
| Indivior Inc.Sublocade | $358 | $40,42019 claims |
| Alkermes, Inc.Lybalvi | $1,032 | $18,25011 claims |
| AbbVieVraylar | $413 | $13,62011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Wilmington
- Paul BuongiornoWilmington$208K
- Craig ChepkeHuntersville$4.1M
- James BarkerHickory$4.1M
- Mark ReynoldsDurham$3.2M
- Oleg TcheremissineCharlotte$2M
- Richard WeislerRaleigh$1.2M
- Dan BlazerDurham$1M
- Samantha Meltzer-BrodyChapel Hill$909K
- Andrew KrystalDurham$754K
- Brian FarahWinston Salem$605K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.